Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Abstract Background Ixekizumab improves signs/symptoms of psoriatic arthritis (PsA). We present an integrated analysis of baseline disease burden and post-baseline outcomes in ixekizumab-treated patients with enthesitis or dactylitis. Methods Data from SPIRIT-P1 and SPIRIT-P2 were integrated. Patien...

Full description

Bibliographic Details
Main Authors: Dafna D. Gladman, Ana-Maria Orbai, Uta Klitz, James Cheng-Chung Wei, Gaia Gallo, Julie Birt, Suchitrita Rathmann, David Shrom, Helena Marzo-Ortega
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Arthritis Research & Therapy
Subjects:
Ixekizumab
Enthesitis
Dactylitis
Psoriatic arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-019-1831-0

Internet

http://link.springer.com/article/10.1186/s13075-019-1831-0

Similar Items